RxDoctor Payments Data

Sweta Chandela, MD

Interventional Cardiology · Voorhees, NJNPI 1962655340

Payments from drug & device makers

$3,050in general payments, 2019–2025

Across 60 payments — averaging $50.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$810
  • Abbott$389
  • Kestra Medical Technology Services, Inc.$309
  • Johnson & Johnson$249
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$199
  • E.r. Squibb & Sons, L.L.C.$171
  • plus $923 from 9 others

What the payments were for

  • Food & beverage$3,050100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,050 in reported general payments places this provider in the 20th percentile of 166 interventional cardiology providers in New Jersey.

See all interventional cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$138,872
Medicare patients
1,549
Services billed
2,588

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban136$163,544
EntrestoSacubitril/Valsartan43$43,487
XareltoRivaroxaban23$28,946
Repatha SureclickEvolocumab16$24,368
BrilintaTicagrelor13$12,636
Metoprolol Succinate284$4,629
Rosuvastatin Calcium180$3,374
Diltiazem 12hr ErDiltiazem Hcl13$2,846
Diltiazem 24hr Er (Cd)Diltiazem Hcl61$2,032
Atorvastatin Calcium184$1,465
Amiodarone Hcl11$1,398
Isosorbide Mononitrate ErIsosorbide Mononitrate82$1,085
Ezetimibe26$903
Metoprolol Tartrate127$893
Flecainide Acetate18$879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$47$43,48743 claims
Johnson & JohnsonXarelto$249$28,94623 claims
AstraZenecaBrilinta$150$12,63613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 166 interventional cardiology providers in New Jersey.

Other interventional cardiology in Voorhees

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →